Why the study?
The safety and effectiveness of different anticoagulant regimens following left atrial appendage occlusion remained to be explored.
Does anticoagulant therapy improve safety and efficacy compared to antiplatelet therapy in patients after left atrial appendage occlusion?
Does anticoagulant therapy improve safety and efficacy compared to antiplatelet therapy in patients after left atrial appendage occlusion?
Anticoagulant therapy (VKAs or NOACs) demonstrates better safety and efficacy than antiplatelet therapy following left atrial appendage occlusion.
Favors anticoagulants over antiplatelets after LAAO to lower DRT and mortality; extends meta-analytic evidence for optimal post-occlusion regimens.
OBJECTIVE: This meta-analysis explored the safety and effectiveness of different anticoagulant regimens after left atrial appendage occlusion (LAAO). METHODS: Databases, such as PubMed, MEDLINE, EMBASE, Web of Science, and Cochrane Library, were searched to identify eligible studies according to the inclusion criteria. The incidences of events, including device-related thrombus (DRT) formation, stroke, systemic thromboembolism, bleeding, cardiovascular mortality, and all-cause mortality, were analyzed using R version 3.2.3. RESULTS: The screening retrieved 32 studies, including 36 study groups and 4,474 patients. The incidence of outcomes after LAAO was calculated via meta-analysis. In the subgroup analysis, the rates of DRT formation, cardiovascular mortality, and all-cause mortality were significantly different among different antithrombotic methods. Single antiplatelet therapy was associated with the highest rate of adverse events, followed by dual antiplatelet therapy (DAPT). Vitamin K antagonists (VKAs) and new oral anticoagulants (NOACs) carried lower rates of adverse events. CONCLUSIONS: Anticoagulant therapy had better safety and efficacy than antiplatelet therapy. Thus, for patients with nonabsolute anticoagulant contraindications, anticoagulant therapy rather than DAPT should be actively selected. NOACs displayed potential for further development, and these treatments might represent alternatives to VKAs in the future.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: